Watch our webinar with Radiopharm Theranostics, featuring Managing Director and CEO Riccardo Canevari. A presentation followed by live Q&A with the audience.

Radiopharm Theranostics (ASX “RAD”) is a clinical stage radiopharmaceutical company developing Therapeutic and Imaging products using peptides, small molecules, nanobodies and antibodies. With three molecules in clinical stage and three molecules in late preclincial, RAD has a very deep pipeline of innovative radiopharmaceuticals.
Management tells one side of the story. Sharewise clients get independent research and Advisor access across ASX, US and global markets.